EPIX ESSA Pharma Accounting Capitalization

ESSA Pharma Inc. (EPIX) focuses on developing specific inhibitors to combat resistant prostate tumors. However, the lack of commercialized drugs and the failure of several tests have erased its pricing power, leaving indicators at 0.11. Meanwhile, the company maintains its status as a scientific leader due to innovative receptor blocking methods. This daily price chart below clearly demonstrates the market valuation of this biotechnological project.

EPIX ESSA Pharma Inc. Book Capitalization (07/04/2022 - 10/25/2025)

Financial and market metric breakdowns for ESSA Pharma Inc (EPIX)

- price and consensus price forecast:

Market Chart ESSA Pharma Inc.|EPIX - Consensus Target

- market capitalization data:

Market Capitalization ESSA Pharma, Inc.|EPIX - Enterprise Value

- book capitalization data:

Accounting Value per Share ESSA Pharma|EPIX - Book Capitalization|Market Capitalization to Book Value Ratio essapharma.com|EPIX - Aggregate Company Assets

- debt and liquidity data:

Debt to Equity Ratio ESSA Pharma Inc.|EPIX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio ESSA Pharma Inc.|EPIX - Company Aggregate Debts|Debts to Book Value ESSA Pharma, Inc.

Summary company analysis:ESSA Pharma - EPIX

Balance capitalization measures the market value of net equity, combining financial reporting data with current quotes to assess the real value of assets minus liabilities. For ESSA Pharma Inc. (EPIX), which invests in bioethical targeted therapy and ESG standards, the current state of balance capitalization serves as an indicator of financial foundation stability during the implementation of costly clinical trials.

Competitors of ESSA Pharma Inc.